AUPH News and Press, Aurinia Pharmaceuticals Inc From 12/04/19

A 357-subject Phase 3 clinical trial evaluating Aurinia Pharmaceuticals' (NASDAQ: AUPH ) lead drug voclosporin, combined with mycophenolate and low-dose corticosteroids, in lupus nephritis patients met the primary and key secondary endpoints. More news on: Aurinia Pharmaceuticals Inc.,...

- Voclosporin achieved statistically superior Renal Response rate (p < 0.001) and comparable safety profile versus standard of care - - Statistically significant results demonstrated in all pre-specified hierarchical secondary endpoints - - Aurinia plans to file an NDA submissi...

- Voclosporin demonstrated fewer adverse effects on beta cell function as compared to tacrolimus in preclinical model of diabetes - - Data supports differentiation of voclosporin versus legacy CNIs and potential best-in-class attributes - - Data to be presented at the Keystone Sym...

Penny Stocks Are Benefiting Big Off Of This Latest Move In Biotech Over the years, it has been seen that investing in penny stocks has often proven to be highly rewarding. So, there is always going to be a lot of interest in these stocks. However, when it comes to picking penny stocks to bu...

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH)  were up 14% at 3:35 p.m. EST on Tuesday as investors anticipated the release of clinical trial data for the biotech's lead drug voclosporin. In October, Aurinia said the last patient had a final study visit in the Aurora phase 3 clinical...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2019 Earnings Conference Call November 14, 2019 4:30 PM ET Company Participants Glenn Schulman - Investor Relations Peter Greenleaf - Chief Executive Officer Dennis Bourgeault - Chief Financial Officer Neil Solomons - Chief Medica...

Aurinia Pharma (NASDAQ: AUPH ): Q3 GAAP EPS of -$0.21 misses by $0.02 . Revenue of $0.23M (-39.5% Y/Y) beats by $0.2M . Press Release More news on: Aurinia Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news,

- Conference call and webcast to be hosted today at 4:30pm EDT – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced the appointment of Ms. Jill...

- Data support differentiation of voclosporin as a potential best-in-class CNI - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multip...